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Abstract 
Pancreatic cancer ranks among the causes of cancer-related deaths. The average size of pancreatic cancer 
during diagnosis is about 31 mm and has not changed significantly over the past 30 years. Poor early diagnosis of 
a tumour has been attributed to the late-presenting symptoms. Over the years, improvement in the diagnosis of 
pancreatic cancer has been observed, and this can be linked to advancement in imaging techniques as well as 
the increasing knowledge of cancer history and genetics. Magnetic Resonance Imaging, Endoscopic Ultrasound, 
and Computer Topography are the approved imaging modalities utilised in the diagnosing of pancreatic cancer. 
Over the years, the management of patients with pancreatic cancer has seen remarkable improvement as reliable 
techniques can now be harnessed and implemented in determining the resectability of cancer. However, only 
about 10% of pancreatic adenocarcinomas are resectable at the time of diagnosis and will highly benefit from a 
microscopic margin-negative surgical resection. Overall, the failure of early tumour identification will result in 
considerable morbidity and mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Pancreatic cancer in recent years has been 
one of the deadliest with an increased mortality rate of 
about 3% of all cancers and about 7% of all cancer 
death in the United States and Europe with an 
estimated five-year survival rate [1]. 
The estimated number of people expected to 
be diagnosed with pancreatic cancer in 2018 is about 
55,440 (29,200 men and 26,240 women), and about 
44,330 (23,020 men and 21,310 women) will die of 
pancreatic cancer [2]. 
Several factors have contributed to an 
increased risk of pancreatic cancer. Such risk factors 
vary from; tobacco use, overweight, obesity, 
workplace exposure to certain chemicals (benzene, 
petrochemicals, dyes, and pesticides), age, gender, 
race, family history, inherited genetic syndromes, 
diabetes, chronic pancreatitis, cirrhosis of the liver, 
stomach problems, diets, physical in-activities, coffee 
and alcohol [2]. 
The signs and symptoms vary due to the 
location and the stage of a tumour. The tumours 
located at the head of the pancreas cause obstructive 
jaundice and weight loss, which occur as a result of 
steatorrhea and diarrhoea. While tumours of the body 
and tail usually lead to abdominal pain and weight 
loss. Pain is also frequently associated with 
pancreatic cancer. The pain usually presents as a 
dull, deep pain, coming from the upper abdomen, 
radiating to the back [3].  
Different case studies have shown that 
patients in the early stages with tumour size less than 
3 cm without lymphatic metastasis have a better 
prognosis with a 5-year survival rate of up to 25-30% 
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following surgical resection of a tumour. This result 
suggests that early detection is essential for the 
treatment and management of the tumour [4]. 
Also, advancement in diagnostic Imaging has 
paved the way in dictating underlining internal 
diseases which do not present with pain at the onset 
as observed in pancreatic cancers. Several imaging 
modalities have been used over the years for the 
diagnosis of different cancers [5]. This review looks at 
the epidemiology, genetics, screening and the 
management of Pancreatic cancer.  
 
Epidemiology of Pancreatic Cancer 
The epidemiological study of pancreatic 
cancer and the rate of its occurrence from 2005 to 
2014 showed stable rates in women with a decline of 
approximately 2% annually in men. The cancer death 
rate from 2006 to 2015 had a 1.5% decrease in its 
annual report for both men and women. The 
combined cancer death rate fell continuously from 
1991 to 2015 by a total of 26%, translating to 
approximately 2,378,600 fewer cancer deaths than 
would have been expected if death rates had 
remained at their peak [6]. 
 
Incidence 
The incidence of pancreatic tumour varies 
from one geographical population to another. In every 
10000, about 7.4 are affected by the tumor in both 
Western Europe and North America. Other developed 
countries such as New Zealand and Australia have 
about 6.5 per 100000 affected with the tumor. Lower 
incidence of approximately 1.0 in every 100000 is 
observed in developing countries in Africa and south-
central Asia [2].  
Pancreatic cancer also varies by gender in 
various geographical regions. The occurrence rate of 
pancreatic cancer among men in 2012 was 4.9 per 
100000 and 3.6 per 100000 in women. The risk of 
developing pancreatic cancer in men was high in 
Armenia (11.9) and Czech Republic (11.8), Slovakia 
and Hungary (equally-11.5), then in Japan and 
Lithuania (equally-10.6). However, the risk of having 
pancreatic cancer in men was lowest in Guinea (0.4) 
and Pakistan (0.5). The incidence of pancreatic 
cancer in women is higher in developed countries. 
The risk of developing the tumour is lowest in 
Polynesia and central Africa (equaling-1.0), while the 
risk is higher in Hungary (5.9), Denmark (5.9), Finland 
(6.2) and Armenia (6.1) [7].  
Europe and North America have 33% of the 
overall occurrence. This reflects on the accuracy of 
the diagnosis rather than the aetiology. The 
differences in incidence around the world have to do 
with quality in the data collected [6]. The incidence of 
pancreatic cancer around the world is summarised in 
Figure 1. 
 
Figure 1: The figure showing the Incidence of pancreatic cancer 
around the world 
 
The overall worldview of pancreatic cancer is 
showing the incidence rate. The incidence rate is 
more pronounced in developed countries than in the 
less developed countries. 
The reduction in mortality incidence, when 
compared to past years, has been due to the 
improvement in medical care. Improved medical care 
showered significant positive effects on cancer 
treatment and management yet leaving some 
loopholes for some cancers such as pancreatic 
cancer [7]. Table 1 relates pancreatic cancer to other 
common cancers in the United States.  
Table 1: Relation of pancreatic cancer to the common types of 
cancers that affect the American population with the estimated 
new cases and deaths for 2018 
Rank Common Types of Cancer Estimated New 
Cases 2018 
Estimated 
Deaths 2018 
1. Breast Cancer (Female) 266,120 40,920 
2. Lung and Bronchus Cancer 234,030 154,050 
3. Prostate Cancer 164,690 29,430 
4. Colorectal Cancer 140,250 50,630 
5. Melanoma of the Skin 91,270 9,320 
6. Bladder Cancer 81,190 17,240 
7. Non-Hodgkin Lymphoma 74,680 19,910 
8. Kidney and Renal Pelvis Cancer 65,340 14,970 
9. Uterine Cancer 63,230 11,350 
10. Leukemia 60,300 24,370 
11. Pancreatic Cancer 55,440 44,330 
 
The table shows the relation of pancreatic cancer to the common types of cancers that 
affect the American population with the estimated new cases and deaths for 2018 [6]. 
 
Despite the improvement in the treatments of 
cancers in general, pancreatic cancer remains one of 
the deadliest cancers to date with high mortality as 
shown in Figure 2. For 2018 projection, new cases 
were estimated at 55,440 (3.2%) and 44,330 (7.3%) 
estimated deaths. The most predominant types of 
cancers are more common in comparison to 
pancreatic cancer. However, the late discovery of 
pancreatic cancer makes treatment and management 
challenging [6]. 
 
Survival Rate 
Survival rate helps to generally estimate life 
expectancy after diagnosing cancer from the available 
data. It aids the comparison of patients diagnosed 
with cancer and the survival of people in the general 
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population within the same age, sex, and race who 
have not been diagnosed with cancer.  
 
Figure 2: New incidence of pancreatic cancer was at 12.6 per 
100,000 men and women annually. The number of mortality was 
10.9 per 100,000 men and women annually. These rates are age-
adjusted and based on 2011-2015 incidence and mortality 
 
It’s also important to note that survival 
statistics are based on large groups of people which 
obstruct the use of it to predict an individual status. No 
two patients are entirely alike, and treatment and 
responses to treatment can vary greatly [6]. The 5-
year relative survival rate about the cancer staging is 
shown in Figure 3.  
 
Figure 3: Five Years Relative Survival. The figure is showing a 5-
year relative survival rate about the staging of cancer. The staging 
is broken down into Localized, Regional, Distant and Unknown. 
 
Cases by Stage 
Cancer staging during diagnosis refers to the 
extent of metastasis in the body. This helps to 
determine treatment options and life expectancy. 
When cancers do not undergo metastasis, it is known 
as localised cancer (stage 1). The spread of cancer to 
part of the body makes it regional or distant (stage II-
IV).  
The earlier a pancreatic cancer is identified, 
the higher the chance of survival rate for the five-year 
interval after being diagnosed. Only about 10.0% of 
pancreatic cancers are diagnosed at the local stage, 
and the 5-year survival rate for localised pancreatic 
cancer is 34.3% [6]. Figure 4 shows the staging of 
pancreatic cancers at the time of diagnosis. 
 
Figure 4: Percent of Case by Stage. The figure shows the staging of 
pancreatic cancer in the American population from 2008-2014 with 
all races, and both exes indicated 
 
Prevalence in Gender, Race, and Ethnicity 
The risk of Pancreatic cancer increases with 
age and more common in men than women. The 
number of new cases of pancreatic cancer was 12.6 
per 100,000 for men and women annually based on 
2011-2015 cases. Future predictions of pancreatic 
cancer at some point in some adults stands at 1.6 per 
cent according to the 2013-2015 data. In 2015, 68,615 
people were estimated to be living with pancreatic 
cancer in the United States [6]. 
The period of 2014-2015 however, showed a 
decline in the occurrence of cancer in comparison to 
previous years. In 2015, the cancer mortality rate 
increased by 14% in non‐Hispanic African Americans 
than non‐Hispanic Caucasians overall. The mortality 
rate ratio was 1.14; with a 95% confidence interval. 
But the racial disparity was much larger for individuals 
aged < 65 years with the mortality rate ratio as 1.31 
and the confidence interval at 95%, compared with 
those aged ≥ 65 years with mortality rate ratio as 1.07 
and the confidence interval at 95%, 1.06‐1.09 [6]. The 
comparison between different races and gender about 
new incidence and mortality has been summarised in 
Table 2 below. 
Table 2: The table compares different race and gender about 
new incidence and mortality 
 MALE FEMALE 
 Incidence Deaths Incidence Deaths 
All Race 14.4 12.6 11.2 9.5 
Caucasian 14.4 12.6 11.1 9.4 
African descent 16.9 14.8 14.3 12.2 
Asian/Pacific Islander 11.0 8.3 9.2 7.3 
American Indian/Alaska 
Native 
11.3 9.7 7.8 8.0 
Hispanic 12.0 9.5 10.5 7.7 
Non-Hispanic 14.7 12.9 11.3 9.7 
 
This shows every new case and death per 
100,000 persons in the population at the time of the 
census [6]. 
 
Genetics of Pancreatic Cancer 
Genetics has become a vital aspect in the 
early detection of pancreatic cancer. The genetics of 
pancreatic cancer is classified into two major origins, 
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the exocrine pancreas, and the neuroendocrine 
pancreas. Among these two origins, 85% of cases 
seen is from the exocrine pancreatic origin which is 
the pancreatic ductal adenocarcinoma [3]. 
Genes like Kras, CDKN2A, TP53, SMAD4 
have been implicated in most cases of pancreatic 
cancer [3], the understanding of this main genes has 
given insight into the diagnosis and treatment of 
pancreatic cancer. However, the main driver genes for 
pancreatic tumour; KRAS (90%), CDKN2A (90%), 
TP53 (70%), SMAD4 (55%) undergo different 
mutations that give rise to carcinogenesis of a 
pancreatic tumour [1]. 
Furthermore, Roboslit pathway (5%), Notch 
signalling (5%), WNT (10%), chromatin (20%), DNA 
repair (17%), cell cycle processing (15%) are the 
minor pathways implicated in pancreatic cancer [8]. 
Kras gene is responsible for 90% of most 
pancreatic cancer cases. RAS protein is responsible 
for cell differentiation and proliferation by sending the 
signals for cell differentiation. The RAS protein binds 
to GTP in G coupled receptor and gives the signal for 
the hydrolyses of GTP to GDP resulting in other 
downstream signals for uncontrolled proliferation and 
growth. The mutation in RAS gene makes the gene 
bind to GTP simultaneously, and signals are given at 
the cellular level for uncontrolled proliferation [9]. 
TP53 is a tumour suppressor gene involved in 
cell cycle, the inactivation of this gene by point 
mutation causes several changes in the cell cycle. 
This causes several cell cycle check points to be 
bypassed, thus inducing gene mutations and hence 
cancer formation. P53 also plays important roles in 
apoptosis by mostly arresting cells in the G1-S phase 
[10]. 
The normal function of the p53 gene is to bind 
to other genes like miRNA34a which codes for p21 
[4]. P21 is a protein that acts as a signal for the 
shutdown of DNA replication. Hence, mutation to p53 
results in the inactivation of the p21 gene and results 
in uncontrolled growth and proliferation [1]. 
CDKN2A is a tumour suppressor gene for 
regulating G1-S phase of the cell cycle in a pancreatic 
tumour. When the CDKN2A gene undergoes 
inactivation, it leads to unregulated and uncontrolled 
growth and differentiation [1]. 
SMAD4 is a tumour suppressor gene which 
activates the attachments of TGFb immediately to cell 
surface receptors. This sends signals into the nucleus 
to turn on the SMAD4 gene to attach themselves to 
other protein to regulate and control the growth and 
proliferation in specific areas of the DNA. Mutation in 
this gene causes uncontrolled proliferation and growth 
which gives rise to pancreatic cancer [1].  
Studies have shown that targeting the Kras 
axis eliminates cancer cells and pancreatic tumour 
formation,
 
so the RAS gene is the major contributing 
factor to pancreatic tumour formation [10].  
A recent study has shown that CCAT2 gene 
which is a long non-coding RNA is the oncogene in 
the development of pancreatic ductal adenocarcinoma 
(PDAC). A total of 80 human PDAC tissues and 3 
PDAC cell lines were assayed, and it was shown that 
there was more CCAT2 expression in the PDAC cell 
lines compared to the normal pancreatic tissues [8].  
Studies have also shown that out of all the 
genes that are responsible for pancreatic cancer, the 
SMAD4/DPC4 gene is a good marker of metastasis 
[11]. The study showed that 641 patients showed 
DPC4/SMAD4 correlation with overall survival and 
recurrence patterns. The inactivation or loss of this 
gene has caused uncontrolled differentiation and 
metastatic development seen in pancreatic cancer 
[11]. 
 
Epigenetics  
There are other genetic mechanisms different 
from the Kras mutation or the tumour suppressor 
deletion; these other mechanisms are also useful in 
the therapeutic management of PDAC [9].  
DNA methylation is one of the mechanisms 
that inactivates suppressor genes. These genes do 
not undergo any mutation, but the cellular level methyl 
groups are added to carbon 5 of the pyrimidine ring 
which silences the gene [10]. Recent studies have 
shown that multiple genes are silenced or methylated 
in 45 pancreatic carcinomas. It was analysed that 
RARb, p16, CACNAIG, TIMP-3, Ecad, THBSI, Hmlh1, 
DAPkinase, MINT31 are genes seen in pancreatic 
cancer [12]. Overexpression of EGF, EGF-R, HER-
2/neu, and p185 has also been found to be common 
in pancreatic tumours of advanced stages [13]. 
It has been observed that some micro-RNAs 
are deregulated in some pancreatic ductal 
adenocarcinomas. MiR-21, for instance, is 
overexpressed in 20 pancreatic carcinoma tissues 
and cell lines compared to normal tissue or cell lines 
[14]. 
Most pancreatic neuroendocrine tumours 
show great phenotypic and genotypic heterogenicity, 
they also occur sporadically or as familial tumours in 
association with other familial diseases like multiple 
endocrine neoplasia types 1 (MEN1), Von Hippel 
Lindau disease (VHL) or tuberous sclerosis [15], [16]. 
In a research carried out by Yuchen Jiao et 
al., in determining the genetic basis of PANnet 
resulted in the discovery that 44% of the tumours had 
somatic mutations in the MEN1 gene, 43% had 
mutation in the DAXX (death domain-associated 
protein) and ATRX gene; they also found a 14% 
mutation in the mTOR gene [17]. 
PHLDA3b which is a tumour suppressor has 
also been implicated in the formation of PANnet, the 
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loss of heterozygosity at high frequency has been 
showed to lead to the development of PANnet, 
methylation of this gene has been implicated in the 
generation of PANnet [18]. 
Aberrant hypermethylation of 11 tumour 
suppressor genes were detected in PANnet, this gene 
includes RASSFIA (75%), ink4a/p16 (40%), OMGMT 
(40%), O-MGMT (40%), RAR-B (25%), hMLHI (23%), 
TIMP3, GSTπ, E-cadherin, P14ARF, APC, the 
aberrant hypermethylation of this gene has been 
associated with advanced tumor stage of pancreatic 
neuroendocrine tumors [19].  
 
Screening Modalities 
Several types of modalities exist in Diagnostic 
Imaging. These modalities act as a benchmark in 
diagnosing pancreatic cancer. The different types of 
imaging vary from computed tomography (CT), 
magnetic resonance imaging (MRI), Positron-emission 
tomography (PET), Ultrasound and Nuclear scans [5]. 
Computed tomography is the combination of 
several x-ray pictures taking at the same time from 
different angles to produce a 3-dimensional image of 
the region been exposed to the CT machine. This 
creates an all-around view of the internal organs and 
structures for better diagnosis and analysis [20]. 
Based on available literature, CT has mostly 
been used in determining the staging of pancreatic 
cancer. However, it has been observed to 
underestimate the spread of cancer which results in 
the need for invasive surgeries or other imaging 
techniques to determine the extent of cancer. The 
combination of other imagines solutions have been 
proven to be more efficient when used together with 
the CT scan [21].
 
The most used combined imaging technique 
in the diagnosis of pancreatic cancer is the CT Scan 
and Positron Emission Tomography (PET Scan). The 
PET Scan utilises nuclear medicine in observing the 
metabolic processes in the body [22].  
This system utilises gamma rays emitted 
indirectly by a positron-emitting radionuclide (tracer). 
The biologically active molecules used during PET 
scan examination aid in the visualisation of interesting 
areas in 3-dimension by reconstructing the image with 
computer analysis [23]. 
The molecule mostly used clinically is 
Fludeoxyglucose (FDG), an analogue of glucose. The 
concentration of this biomarker helps in showing the 
metabolic rate of tissues which in most cases 
indicates high metastasis in the presence of cancer 
[24]. 
Another imaging modality which is safer than 
the CT and PET scan relation to radiation emitted 
during the scanning process is Magnetic Resonance 
Imaging (MRI). It is used in conditions where the data 
for nonrigid motion characterised as tumour and 
organs will be at risk of radiation therapy. It also helps 
in identifying soft tissues such as blood vessels about 
tumour growth. The image produced is also in 4 
dimensions like that of CT scan with some structural 
changes [25]. 
In an observation carried out in Karolinska 
University Hospital between 2010 and 2013, using an 
MRI procedure. All patients with the genetic risk 
associated with pancreatic mutations were checked 
[25]. This gave a clearer understanding of the MRI 
potential in identifying precancerous or early cancers 
in individuals at risk for pancreatic cancer. Based on 
the study it showed how effective the procedure and 
protocol used was in the early dictation of cancer [25]. 
Endoscopic Ultrasound (EUS) is the most 
accurate form of ultrasound useful in the diagnosis of 
pancreatic cancer. This imaging modality is achieved 
by a small ultrasound probe on the tip of an 
endoscope, which is a thin and flexible tube used in 
looking inside the digestive tract [26]. 
This procedure can be done in place of 
having a large opened incision to explore the extent of 
cancer. The procedure involves the probe being 
passed through the mouth down to the first part of the 
small intestine. It is then pointed towards the pancreas 
to view the extent of the tumour and take a biopsy for 
confirmation [26]. 
 
Factors that Affects Screening 
Pancreatic cancer screening mainly focuses 
on people with an increased risk of developing the 
disease. Some of these risk factors include; smoking, 
diet, diabetes mellitus, obesity [2]. Individuals in the 
population with a family history of pancreatic cancer 
are also at risk; some genetic syndromes also pose 
risk factors of pancreatic cancer [2]. 
Screening is recommended for individuals 
considered to be at high risk of developing pancreatic 
cancer, individuals with > 5% lifetime risk [27]. The 
family history is the main tool used to determine 
pancreatic cancer risk; the number of affected family 
members and the relationships among the individuals 
(especially first-degree relatives) at risk is used as the 
basis for risk assessment [28]. The incidence of 
pancreatic cancer as relating to the number of 
affected first-degree relatives is summarised in Table 
3. 
Table 3: Table shows the incidence of pancreatic cancer by 
some affected first-degree relatives [33] 
First degree relatives Incidence ratio Incidence per 10
4
 
1 4.5 x 41 
2 6.4 x 58 
> 3 32.0 x 288 
 
The chances of occurrence of pancreatic 
cancer in an individual increase with the number of 
family members with pancreatic cancer. Familial 
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pancreatic cancer (FPC) is defined as having 2 or 
more of first-degree relatives with pancreatic cancer 
that does not meet the criteria of other hereditary 
cancer syndromes [29]. Familial pancreatic cancer 
accounts for at least 4-10% of pancreatic cancer. 
According to Matsubayashi H et al., European 
countries have been reported in FPC families, also 
seen in other hereditary syndromes; occurrence at a 
younger age and the worse prognosis are seen in the 
late years [30]. The resected pancreases of FPC 
relative often show multiple pancreatic intraepithelial 
neoplasia (PanIN) foci [31].  
Individuals with mutations in the BRCA2, 
PALB2, p16, STK11, ATM, PRSS1, and HNPCC 
genes are associated with significantly increased risk 
for Pancreatic cancer and need to be screened [32]. 
These gene mutations are responsible for 10% of the 
familial susceptibility to pancreatic cancer [27]. 
Patients with Peutz Jegher syndrome also have an 
increased risk of pancreatic cancer [29]. 
 
Management of Pancreatic Cancer 
Like various tumours or malignancies in the 
human body, it requires precise staging to determine if 
the tumor is respectable. The resectable nature of the 
tumour indicates the extent of its metastasis. This 
knowledge helps in choosing the best course of 
treatment and management [6].  
The criteria for resectable pancreatic cancer 
are determined by the borderline of the tumour in 
contact with the superior mesenteric artery, a small 
segment of the celiac artery and the whole common 
hepatic artery [33]. However, the obstruction of the 
superior mesenteric artery and portal vein confluences 
caused by tumor growth is fixable by minimally 
inversive surgery [34]. 
Staging can only be very effective if the 
imaging of the malignancy is done with utmost 
accuracy. Most of the imaging techniques have one 
disadvantage or the other, but in cases where the 
advantage outweighs the disadvantage, they deemed 
fit for investigations [27]. 
However, there are some hurdles during the 
management which include; 
1. Most patients are in the age group of the 
late sixties (70%) which undeniably predisposes them 
to multiple morbidities. 
2. Some chemotherapeutic agents used 
during therapy present with other symptoms which 
affect the patient’s functionality.  
3. In addition to the reduced potency of 
chemotherapy; pancreatic cancer does not comply 
well with chemotherapy making treatment options 
restricted and cumbersome. The assessment of the 
effect of chemotherapy has been challenging due to 
the dense desmoplastic reaction (this refers to the 
growth of dense fibrous tissue around the tumour 
stimulated by various factors especially TGF-β) 
exhibited by pancreatic malignancies. 
4. Obtaining biopsy samples from the tumor is 
difficult. However, chemotherapy has the capability of 
targeting specific cancerous cells [27].  
Following the prognostic classification of 
pancreatic cancer, surgical intervention is only 
applicable to resectable tumours [10], [16]. 
Neoadjuvant therapy for resectable pancreatic cancer 
has shown varying results due to limited sample size 
and different patient responses to the therapies. The 
different means of classification has also led to the 
different types of therapy being used in the pre, peri 
and postoperatively state [16]. However, the data 
supporting its benefits justify its use [31].  
Gemcitabine, a well-known medication has 
significantly increased the survival rate of patients with 
pancreatic cancer. Although, this comes with a heavy 
price in terms of negative side effects. Therefore, 
various combination therapies are being used to 
reduce side effects and be of more benefit than harm 
[31], [35]. 
Preoperatively Cisplatin in combination with 
gemcitabine significantly increases the resection rate 
by 70% which is almost doubled the rate of 
gemcitabine alone at 38% [33]. Studies were done by 
Adamska et al., (2017) also shows an overall survival 
rate of 21% alive and pancreatic cancer free with this 
combination therapy [31]. Gemcitabine in combination 
with capecitabine, oxaliplatin and docetaxel improve 
resection rates in comparison with Gemcitabine alone 
[31], [33]. Borderline resectable patients treated with 
Xeloda, Taxotere, Gemzar, and radiation showed that 
55 patients were able to have microscopically margin-
negative resection out of 57 who were treated [1]. 
Neoadjuvant therapy for locally advanced and 
metastatic pancreatic cancer is more restricted due to 
the advanced state of cancer. The area concerned is 
more widespread and would involve lymph nodes in 
the case of metastasis. The effect of the drugs on 
other parts of the body can vary per individual. Nab-
paclitaxel and Gemcitabine accompanied by Folfirinox 
therapy showed tumour regression and 
microscopically margin-negative resection of the 
tumour [16]. Other combinations which are also used 
for resectable and borderline resectable pancreatic 
cancer like Gemcitabine and cisplatin, gemcitabine 
and oxaliplatin, gemcitabine and capecitabine, PDXG 
(docetaxel, gemcitabine, capecitabine, and cisplatin) 
have also shown fairly good results encouraging the 
use of neoadjuvant in such patients [31]. 
The prognosis of resectable, borderline 
resectable and some locally advanced pancreatic 
cancer has a better probability for survival if managed 
properly. However, metastatic pancreatic cancer 
survival is solely based on increased therapies and 
palliative care [31].  
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Side Effects and Benefits of Therapy  
The common side effects of some of the 
medications are neutropenia, thrombocytopenia. 
Examples of drugs which cause this side effect 
include 5-FU and gemcitabine, gemcitabine and 
erlotinib, gemcitabine and cisplatin, gemcitabine and 
nab-paclitaxel, FOLIFIRINOX which is a combination 
of fluorouracil, leucovorin, irinotecan, and oxaliplatin 
[31], [35]. 
The benefits of the monotherapy of 
gemcitabine include improved disease induced 
symptoms and increased survival response. However, 
it comes with several side effect except for 
haematological problems [35]. 
Benefits of novel agents include a reduction in 
pain, increased survival rate. Common side effects 
are haematological effects, musculoskeletal toxicities 
[35]. Examples include molecular targeting (olaparib), 
mitochondrial targeting (mFOLFIRINOX), 
microenvironment targeting tumor-associated-
macrophages (CCR2 selective inhibitors), RAS 
inhibitors (Tipifarnib), metalloproteinase inhibitors 
(marimastat, BAY12-9566), epidermal growth factor 
receptor antagonist (erlotinib, trastuzumab, ZD1839), 
Antiangiogenics (thalidomide, paclitaxel, 
bevacizumab, combretastatin) [31]. 
Post-surgical patients are given adjuvant 
therapy, preferably gemcitabine or gemcitabine and 
capecitabine, although other regimens could be used. 
The use of other regimens is dependent on the 
response of the patients [35]. 
 
 
Discussion 
 
Pancreatic cancer has been shown to have 
poor prognosis over the years. The disease falls 
within the most common causes of cancer-related 
deaths yet has a very low occurrence in comparison 
to the leading causes of cancer-related deaths. The 
availability of various diagnostic tools, treatment, and 
management have helped to contain the mortality of 
the tumour [1]. 
The study of pancreatic cancer from 2014 to 
2015 showed a decline in mortality in men and a 
stable state in a woman. However, the decline in men 
is not significant enough to be considered clinically 
relevant [2]. The phenomenon seen between men and 
women is however not clear. Although, the decline in 
mortality for men can be correlated with the 
improvement in the health sector.  
Research has shown that pancreatic cancers 
show good survival rates when diagnosed early [5]. 
Statistically, an increase of about 14% in mortality rate 
is seen in African Americans [7].  
Genes like Kras, CDKN2A, TP53, SMAD4 
have been the point of interest in most cases of 
pancreatic cancer. The breakthrough in diagnostic 
techniques has paved the way for further examination 
to conclude early enough if an individual is at risk or 
has the tumour and guide early treatment or 
management. 
Available research on pancreatic cancer 
indicates that genetics plays a vital role in detecting 
patients prone to developing the tumour [9]. Certain 
genes in the genetic line-up act as precursors for 
pancreatic cancer [16]. This understanding aids in 
further examination such as diagnostic imaging to 
confirm the state of the pancreas. 
As shown by the literature, diagnostic imaging 
has over the years made some tremendous strides in 
aiding early detection of pancreatic cancer. Research 
has shown that MRI and EUS diagnostic technique is 
one of the best means of diagnosing pancreatic 
cancer without having to expose the patients to 
radioactive rays [25] further.  
Various factors have been shown to cause 
pancreatic cancer. These factors mostly affect those 
who are genetically prone to having cancer. For 
instance, smoking acts as a carcinogen when used by 
genetically prone individuals [2]. The extreme 
exposure to some of the imagine radiations such as 
from x-rays and CT scans can escalate the dormant 
state [25]. 
The treatment and management of pancreatic 
cancer have improved between the 90s to date 
showing a decrease in mortality [35]. These 
improvements are all due to the advancement in 
technologies and medications.  
The technological improvement includes the 
use of procedures such as interventional radiology. 
This improvement has aided in the precise removal of 
tumours with quick recovery time [5]. The medications 
Cisplatin and gemcitabine are helpful in tumour 
resectability. Radiation therapy with the combination 
of Taxotere and Gemzar also showed improvement in 
tumour resectability. Nab-paclitaxel and gemcitabine 
accompanied by folfirinox therapy significantly have 
been shown to help in the regression of the pancreatic 
tumour [16]. The medications also improve the 
disease-induced symptoms and increase survival 
response. However, the use of these medications is 
not devoid of side effects such as haematological and 
musculoskeletal toxicities [35]. 
 
 
Conclusion 
 
Pancreatic cancer has had a history of poor 
prognosis because of its late detection. A family 
history of pancreatic cancer closely followed up with a 
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genetic screen has the potential to predict the likely 
incidence, early detection and possible management 
of pancreatic cancers. Also, further screening 
modalities and investigations using imaging 
techniques and interventional radiology have also 
helped to improve the early diagnosis and 
management of pancreatic cancer.  
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